NR4A1 and breast carcinoma: Additionally, the phase III AMEERA-6 trial (NCT05128773) evaluates the safety and efficacy of amcenestrant vs tamoxifen in patients with hormone receptor–positive early breast cancer who discontinued adjuvant AIs because of treatment-related toxicity.